253-50-9

Basic information

• Product Name: 2,6-Naphthyridine(7CI,8CI,9CI)
• Synonyms: 2,6-Naphthyridine(7CI,8CI,9CI);2,6-naphthyridine
• CAS NO: 253-50-9
• Molecular Formula: C₈H₆N₂
• Molecular Weight: 130.15
• Product Categories: PYRIDINE
• Mol File: 253-50-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 114-115 °C
• Boiling Point: 286.5°C at 760 mmHg
• Flash Point: 108°C
• Appearance: /
• Density: 1.183g/cm³
• Vapor Pressure: 0.00453mmHg at 25°C
• Refractive Index: 1.653
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.00±0.10(Predicted)
• CAS DataBase Reference: 2,6-Naphthyridine(7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Naphthyridine(7CI,8CI,9CI)(253-50-9)
• EPA Substance Registry System: 2,6-Naphthyridine(7CI,8CI,9CI)(253-50-9)

Safety Data

• Hazardous Substances Data: 253-50-9(Hazardous Substances Data)

Usage

General Description

2,6-Naphthyridine (7CI,8CI,9CI) is a chemical compound with the molecular formula C8H6N2. It is a heterocyclic aromatic compound consisting of a six-membered ring fused to a five-membered ring with two nitrogen atoms. 2,6-Naphthyridine is considered a potential drug intermediate and is used in the synthesis of pharmaceuticals and agrochemicals. It is also known for its antiviral and antibacterial properties, making it a valuable compound for the development of new medicines. Additionally, it is used as a building block in the production of various organic compounds and materials.

InChI:InChI=1/C8H6N2/c1-3-9-6-8-2-4-10-5-7(1)8/h1-6H

Upstream product

• 1003-73-2 3-picoline-N-oxide 
• 80935-77-9 1,2-dihydro-2,6-naphthyridin-1-one 
• 80935-76-8 N,N-dimethylamino-2-(4-cyano-3-pyridyl)ethene 
• 7584-05-6 3-methyl-4-cyanopyridine 
• 70201-43-3 3-bromo-pyridine-4-carbaldehyde 
• 626-55-1 3-Bromopyridine 
• 222167-62-6 3-(trimethylsilylethynyl)pyridine-4-carboxaldehyde 
• 80935-78-0 1-chloro-[2,6]naphthyridine 

Downstream Products

• 31786-18-2 1,2,3,4-tetrahydro-2,6-naphthyridine 
• 80935-81-5 1-amino-2,6-naphtyridine 

Relevant articles and documents

Cyanido-Bridged FeII–MI Dimetallic Hofmann-Like Spin-Crossover Coordination Polymers Based on 2,6-Naphthyridine

Two new 3D spin-crossover (SCO) Hofmann-type coordination polymers {Fe(2,6-naphthy)[Ag(CN)2][Ag2(CN)3]} (1; 2,6-naphthy = 2,6-naphthyridine) and {Fe(2,6-naphthy)[Au(CN)2]2}·0.5PhNO2 (2) were synthesized and characterized. Both derivatives are made up of infinite stacks of {Fe[Ag(CN)2]2[Ag2(CN)3]}n and {Fe[Au(CN)2]2}n layered grids connected by pillars of 2,6-naphthy ligands coordinated to the axial positions of the FeII centers of alternate layers. The in situ generated [Ag2(CN)3]– linkers define wide rectangular windows that favor the interpenetration of three identical 3D networks, strong argentophilic interactions between them, and the generation of a densely packed structure without accessible void spaces. In contrast, the smaller rhombus-shaped window in 2 affords a structure made up of doubly interpenetrated 3D networks with strong aurophilic interactions between them and accessible voids partially occupied by nitrobenzene molecules. Compound 1 displays a relatively abrupt two-step SCO in the temperature interval 150–215 K, whereas 2 features an incomplete one-step SCO behavior (T1/2 = 166 K) that extends over 150 K.

High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors

The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57-617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active compounds, whereas three series returned active hits. Structure-activity studies demonstrated that the 4-benzoylpyrrole-2-carboxamide pharmacophore had excellent potential for further development. The minimum kinase binding pharmacophore was identified, and key examples demonstrated good selectivity for ERK5 over p38α kinase.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.